Entering text into the input field will update the search result below

Vaccitech: Aiming For A Cure In Chronic Hepatitis B

Apr. 03, 2022 7:57 PM ETBarinthus Biotherapeutics plc (BRNS)5 Comments


  • Vaccitech is known to be the spin-off from Oxford University behind AstraZeneca's SARS-Cov-2 vaccine.
  • The stock suffered from a massive sell-off and is now trading below net cash.
  • Science is promising and upcoming catalysts could lead to a rally of this oversold stock.
  • We are reviewing their main product, ChAdOx1/2 vaccines, and its MVA boost in the context of chronic hepatitis B.

Diseased liver on abstract medical background. 3d illustration

Mohammed Haneefa Nizamudeen/iStock via Getty Images

Presentation and investment thesis

Vaccitech (VACC) is a clinical-stage biotechnological company, spun off from Oxford University. The firm has been recently highlighted as the company which developed the technology behind AstraZeneca's (

This article was written by

MD-PhDInvesting in biotechnologies, medical technologies and healthcare equities. Occasionally, I publish some of my researches in the field.Mainly driven by fundamental analysis, in-depth comprehension of the product of the firm and by understanding how it will translate into real-world trends.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in VACC over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (5)

biogenius profile picture
Great article! The combination with Arbutus RNAi will also be interesting.
Thank you, I’m a believer in the company, riding it down before it goes back up. Other than the hepatitis result in H2 2022 are there any other dates set that could be catalysts? All 2023 or beyond?
BioFlamingo Research profile picture
@Charterboy In 2022, an other catalyst could be the interim analysis of of the Phase1/2 of VTP-200, their product designed against HPV. It is expected for Q4. Also to note, the firm plans to announce the initiation of the Phase 1/2 of their prostate cancer therapeutic in Q3.
@BioFlamingo Research I’m still following VACC, the acquisition of Avidea is under appreciated in my opinion. This gives them additional future pipelines in oncology and autoimmune disease. Avidea had an impressive board of experts and it’s founders were also associated with Oxford at one point. So the synergies here seem to be incredibly positive, vaccitech will soon be very formidable.
Collegiatus profile picture
Thanks for the article. I add it to my watchlist...
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About BRNS

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on BRNS

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.